• Contact us: 01476 247 007
    Yellow fever vaccineYellow fever vaccineYellow fever vaccineYellow fever vaccine
    • How can we help
      • Pharmacovigilance
        • National contact person for pharmacovigilance – post Brexit
        • Pharmacovigilance Standard Operating Procedure Audits
        • Post Marketing Pharmacovigilance Support
        • Clinical Trial Pharmacovigilance Support
        • EU QPPV Provision
        • Quality & Compliance
        • Risk Assessment and Management
        • Signal Detection and Management
      • Medical Writing
      • Patient Information
      • Regulatory
      • Market Authorisation Holding
    • Brexit
    • Our Partners
      • Marti Farm
      • Affiliates
      • Medilink
      • External Team
    • News
    • Get in touch
    Breast Implants Safety Concerns – the Importance of Post-Marketing Surveillance
    4th April 2019
    Pure Drug Safety sponsors Medilink East Midlands Outstanding Achievement Award
    Pure Drug Safety Sponsor Medilink East Midlands ‘Outstanding Achievement Award’
    21st November 2019

    Yellow fever vaccine

    22nd July 2019

    Yellow fever vaccine – following two fatalities – the vaccine must not be given to patients that present with a history of thymus dysfunction, or is immunosuppressed. The MHRA advise clinicians use extreme caution in administering the vaccine in people over 60 due to an increased risk of an Adverse Reaction – ADR

    The use of Valoprate medicines pre and during pregnancy. Valoprate is a medicine used in the treatment of epilepsy and bipolar condition. It has been known that this drug causes significant birth defects in children born to patients using valproate. The MHRA has provided a revised Annual Risk Acknowledgement for clinicians to use on all females of childbearing age. They issued a reminder that there is no safe dose of valproate that can be used in pregnancy.

    Share

    Related posts

    MHRA post-transition period information from Pure Drug Safety
    3rd September 2020

    MHRA post-transition period information


    Read more
    What happens after Brexit for Pharmacovigilance and Regulatory?
    12th February 2020

    What happens after Brexit for Pharmacovigilance and Regulatory?


    Read more
    Pharmacovigilance (QPPV) provision post-Brexit
    7th February 2020

    Pharmacovigilance (QPPV) provision post-Brexit


    Read more

    PLEASE NOTE OUR NEW PHONE NUMBER AS OF 1st JUNE 2021
    Call our team +44(0) 1476 247 007
    email info@puredrugsafety.com



    Sign up for our newsletter

    Pure Drug Safety Ltd

    Pure Drug Safety Ltd · 1 year ago
    @PureDrugSafety



    Many clients have already put their NCPP in place with us here at PDS and are ready for January 2022.

    Read more 👉 https://t.co/6mnM9Dzoma

    #NationalContactPerson #KnowledgeablePerson #ExperiencedQppv https://t.co/rS2W4PZbDv

    View on Twitter


    0

    0

    © 2019 - 2023 Pure Drug Safety.
    As of 1st June 2021 NEW OFFICE & REGISTERED ADDRESS: BioCity Nottingham, Pennyfoot Street, Nottingham, NG1 1GF, UK
    Pure Drug Safety Limited is a company registered in England and Wales. Registered Company Number 7702236. VAT Registered Number 117 966 288
    For our GDPR and Privacy Policy click here
    Designed by Gather Creative | Content managed by Tailored Marketing Solutions | Built + Hosted by GIGER MEDIA